Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Caladrius Biosciences to Participate at Upcoming December Conferences
By: GlobenewsWire - 02 Dec 2019Back to overview list

BASKING RIDGE, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the Company will present at the following conferences in December:

16th Cardio Vascular Clinical Trialists Forum

Date & Time:Thursday, December 5, 2019 at 3:30pm (ET)
Presenter:Douglas W. Losordo, M.D., FACC, FAHA, Chief Medical Officer at Caladrius Biosciences
Location:Embassy of France in Washington D.C.

BioNJ’s Cybersecurity Awareness Breakfast Briefing

Date & Time:Thursday, December 12, 2019 at 8:30am (ET)
Presenter:Greg Berkin, MSc, Vice President of IT and Cybersecurity and Chief Information Officer at Caladrius Biosciences
Location:Princeton Innovation Center BioLabs in Princeton, NJ

About Caladrius Biosciences
Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and  recipient of a RMAT designation in the U.S.A. For more information on the company, please visit www.caladrius.com

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone:  +1-908-842-0084
Email: jmenditto@caladrius.com

Related companies:Caladrius Biosciences, Inc
Copyright 2019 GlobenewsWire Back to overview list
to the top ↑